The Food and Drug Administration’s decision to limit the use of the Johnson & Johnson COVID-19 vaccine won’t have a significant impact on health systems.
The FDA scaled back the emergency use authorization of the vaccine developed by J&J and its Janssen Pharmaceuicals subsidiary because it caused a rare blood clotting disorder in 60 patients out of 18.7 million doses administered. The vaccine should only be used for adults who would otherwise go unvaccinated or who cannot have the Pfizer and Moderna vaccines, the agency said.
Most patients received Pfizer and Moderna’s mRNA vaccines and providers have stored minimal amounts of the J&J vaccine, several health systems said. The J&J shot only accounts for about 3.4% of the 578 million doses of the COVID-19 vaccine administered, according to Centers for Disease Control and Prevention data.
None of Yale New Haven Health’s patients experienced any serious side effects from the J&J vaccine, and most went on to get a mRNA booster, said Dr. Ohm Deshpande, vice president of population health & clinical financial services at Yale New Haven Health.
“We have not received any significant feedback since the FDA’s most recent admission,” she wrote in an email, adding that the health system has worked closely with patients who received the J&J vaccine as new data comes to light. Yale New Haven Health did not have data regarding whether patients who received the J&J vaccine received more follow-up care than those who received Pfizer’s or Moderna’s.
Both Yale New Haven Health and University of Utah Health have kept minimal amounts of the J&J vaccine on hand.
The J&J vaccine has been difficult to obtain, which has likely limited its distribution across the healthcare supply chain, said Erin Fox, senior pharmacy director at University of Utah Health.
